ProCE Banner Activity

TROPiCS-02: OS With Sacituzumab Govitecan vs Treatment of Physician’s Choice for HR+/HER2- Advanced Breast Cancer

Slideset Download
Conference Coverage
Results from the phase III TROPiCS-02 study showed that sacituzumab govitecan improved OS compared with physician’s choice of single-agent chemotherapy in patients with previously treated HR+/HER2- advanced breast cancer.Results from the phase III TROPiCS-02 study showed that sacituzumab govitecan improved OS compared with physician’s choice of single-agent chemotherapy in patients with previously treated HR+/HER2- advanced breast cancer.

Released: September 13, 2022

Expiration: September 12, 2023

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

BMS

Exelixis, Inc.

Gilead Sciences, Inc.

Merck Sharp & Dohme Corp